CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2019—PerkinElmer, in collaboration with Helix, launched a genetic screening test called GenePrism: Actionable Insights, which analyzes a subset of 59 medically actionable genes, including BRCA1 and BRCA2, identified by the American College of Medical Genetics and Genomics. Users’ DNA is sequenced by Helix and results are interpreted at PerkinElmer Genomics using the company’s Ordered Data Interpretation Network software. Individuals who purchase the test from Helix must first complete a medical questionnaire and receive physician authorization before submitting a DNA sample.
Pages: 1 2